The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is a huge mover today! About 901,140 shares traded hands or 40.45% up from the average. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 52.08% since April 4, 2016 and is downtrending. It has underperformed by 53.17% the S&P500.
The move comes after 9 months positive chart setup for the $276.00 million company. It was reported on Nov, 4 by Barchart.com. We have $5.24 PT which if reached, will make NASDAQ:SPPI worth $138.00M more.
According to Zacks Investment Research, “Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum’s expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.”
Insitutional Activity: The institutional sentiment increased to 3.84 in 2016 Q2. Its up 2.68, from 1.16 in 2016Q1. The ratio increased, as 7 funds sold all Spectrum Pharmaceuticals, Inc. shares owned while 18 reduced positions. 34 funds bought stakes while 62 increased positions. They now own 106.93 million shares or 131.39% more from 46.21 million shares in 2016Q1.
Voya Management Ltd Liability Corp has invested 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Deutsche Savings Bank Ag last reported 0.01% of its portfolio in the stock. New York State Common Retirement Fund, a New York-based fund reported 61,300 shares. Blackrock Advsrs Ltd holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 99,210 shares. Pacad Inv Limited accumulated 24,753 shares or 0.02% of the stock. Secor Advsrs Lp owns 218,519 shares or 0.18% of their US portfolio. Cubist Systematic Strategies Ltd Liability, a Connecticut-based fund reported 26,525 shares. Dimensional Fund Advisors Limited Partnership accumulated 0.01% or 1.39M shares. Jacobs Levy Equity Management last reported 0.03% of its portfolio in the stock. The Ontario – Canada-based Royal State Bank Of Canada has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Quantitative Systematic Strategies Ltd Liability reported 24,942 shares or 0.08% of all its holdings. Wellington Gru Inc Llp holds 0% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 398,175 shares. Nationwide Fund Advsrs accumulated 0% or 104,516 shares. The Tennessee-based First Mercantile Trust has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Psagot Invest House Ltd holds 0.01% or 29,886 shares in its portfolio.
More important recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: Businesswire.com which released: “Spectrum Pharmaceuticals Announces Third Quarter 2016 Financial Results …” on October 27, 2016, also Businesswire.com published article titled: “Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update”, Prnewswire.com published: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Spectrum …” on October 06, 2016. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was released by: Globenewswire.com and their article: “INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Spectrum …” with publication date: October 31, 2016.
SPPI Company Profile
Spectrum Pharmaceuticals, Inc., incorporated on November, 18, 2002, is a biotechnology company. The Firm operates through developing and commercializing oncology and hematology drug products segment. The Firm has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. The Company’s commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. The Company’s other products include SPI-2012, POZIOTINIB and EOQUIN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.